42C — IX Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- SG$39.95m
- SG$39.87m
- SG$5.91m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15.9 | 5.66 | 6.21 | 13.5 | 6.53 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.43 | 1.3 | 1.82 | 1.98 | 3.05 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 18.5 | 8.14 | 9.35 | 16.8 | 11 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.64 | 8.29 | 8.95 | 7.72 | 8.22 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 26.7 | 17 | 18.9 | 28.5 | 24.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.53 | 3.3 | 3.67 | 7.86 | 7.17 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.19 | 6.81 | 7.15 | 8.77 | 9.08 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 20.5 | 10.2 | 11.7 | 19.7 | 15.9 |
Total Liabilities & Shareholders' Equity | 26.7 | 17 | 18.9 | 28.5 | 24.9 |
Total Common Shares Outstanding |